Rebecca C. Larson

4.8k total citations · 3 hit papers
38 papers, 3.1k citations indexed

About

Rebecca C. Larson is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Rebecca C. Larson has authored 38 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 16 papers in Molecular Biology and 13 papers in Immunology. Recurrent topics in Rebecca C. Larson's work include CAR-T cell therapy research (28 papers), Immune Cell Function and Interaction (7 papers) and CRISPR and Genetic Engineering (7 papers). Rebecca C. Larson is often cited by papers focused on CAR-T cell therapy research (28 papers), Immune Cell Function and Interaction (7 papers) and CRISPR and Genetic Engineering (7 papers). Rebecca C. Larson collaborates with scholars based in United States, United Kingdom and France. Rebecca C. Larson's co-authors include Marcela V. Maus, Terence H. Rabbitts, A. Förster, Paul C. Nathan, Amanda A. Bouffard, W. B. Currie, George G. Ignotz, Andrea Schmidts, Irene Scarfò and Stefanie R. Bailey and has published in prestigious journals such as Nature, Nature Communications and Nature Genetics.

In The Last Decade

Rebecca C. Larson

37 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recent advances and discoveries in the mechanisms and functions of CAR T cells

2021 553 citations Rebecca C. Larson, Marcela V. Maus Nature reviews. Cancer profile →
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

2019 426 citations Bryan D. Choi, Xiaoling Yu et al. Nature Biotechnology profile →
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours

2022 225 citations Rebecca C. Larson, Michael C. Kann et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rebecca C. Larson United States	19	1.9k	1.3k	947	679	630	38	3.1k
Cindy Delbrook United States	16	2.9k 1.5×	760 0.6×	792 0.8×	715 1.1×	880 1.4×	27	3.3k
Brenda Aguilar United States	19	2.1k 1.1×	728 0.6×	1.0k 1.1×	750 1.1×	585 0.9×	40	2.7k
Brian G. Till United States	26	2.9k 1.5×	988 0.8×	1.0k 1.1×	725 1.1×	725 1.2×	135	3.5k
Olga Shestova United States	27	1.7k 0.9×	1.9k 1.5×	1.5k 1.5×	318 0.5×	597 0.9×	71	4.0k
Marco Ruella United States	29	3.2k 1.7×	1.3k 1.0×	1.3k 1.4×	809 1.2×	1.1k 1.7×	124	4.0k
Karin Straathof United States	23	3.6k 1.9×	1.2k 1.0×	1.9k 2.0×	793 1.2×	1.4k 2.1×	38	4.6k
Keichiro Mihara Japan	21	1.2k 0.6×	914 0.7×	645 0.7×	278 0.4×	340 0.5×	70	2.4k
Catherine Lindgren United States	19	2.5k 1.3×	691 0.5×	1.1k 1.1×	643 0.9×	801 1.3×	40	2.9k
Matthew J. Frigault United States	25	2.9k 1.5×	885 0.7×	851 0.9×	951 1.4×	717 1.1×	131	3.4k

Countries citing papers authored by Rebecca C. Larson

Since Specialization

Citations

This map shows the geographic impact of Rebecca C. Larson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca C. Larson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca C. Larson more than expected).

Fields of papers citing papers by Rebecca C. Larson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca C. Larson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca C. Larson. The network helps show where Rebecca C. Larson may publish in the future.

Co-authorship network of co-authors of Rebecca C. Larson

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca C. Larson. A scholar is included among the top collaborators of Rebecca C. Larson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca C. Larson. Rebecca C. Larson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Korell, Felix, Michael Olson, Diego Salas‐Benito, et al.. (2024). Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics. Science Translational Medicine. 16(750). eadk7640–eadk7640. 14 indexed citations

Grauwet, Korneel, Trisha R. Berger, Michael C. Kann, et al.. (2024). Stealth transgenes enable CAR-T cells to evade host immune responses. Journal for ImmunoTherapy of Cancer. 12(5). e008417–e008417. 8 indexed citations

Larson, Rebecca C., Michael C. Kann, Charlotte Graham, et al.. (2023). Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. Nature Communications. 14(1). 7509–7509. 23 indexed citations

Kann, Michael C., Emily M. Schneider, Amanda A. Bouffard, et al.. (2023). Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7. Leukemia. 38(3). 590–600. 4 indexed citations

Nix, Matthew A., Huimin Geng, Rebecca C. Larson, et al.. (2023). Affinity Matured CD72 CAR-T Improves Efficacy Versus Low Antigen Density B-Cell Non-Hodgkin Lymphoma Models. Blood. 142(Supplement 1). 2068–2068. 1 indexed citations

Larson, Rebecca C., Michael C. Kann, Stefanie R. Bailey, et al.. (2022). CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature. 604(7906). 563–570. 225 indexed citations breakdown →

Arafeh, Rand, Sydney Gang, Taylor E. Arnoff, et al.. (2022). Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. Cancer Research. 83(4). 613–625. 16 indexed citations

Gallagher, Kathleen, Mark B. Leick, Rebecca C. Larson, et al.. (2022). Differential T-Cell Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in mRNA-1273– and BNT162b2-Vaccinated Individuals. Clinical Infectious Diseases. 75(1). e869–e873. 6 indexed citations

Joung, Julia, Paul C. Kirchgatterer, Ankita Singh, et al.. (2022). CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nature Communications. 13(1). 1606–1606. 73 indexed citations

10.

Leick, Mark B., Harrison Silva, Irene Scarfò, et al.. (2022). Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 40(5). 494–508.e5. 88 indexed citations

11.

Jan, Max, Irene Scarfò, Rebecca C. Larson, et al.. (2021). Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Science Translational Medicine. 13(575). 180 indexed citations

12.

Larson, Rebecca C. & Marcela V. Maus. (2021). Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nature reviews. Cancer. 21(3). 145–161. 553 indexed citations breakdown →

13.

Schmidts, Andrea, Amanda A. Bouffard, Angela C. Boroughs, et al.. (2020). Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. Journal for ImmunoTherapy of Cancer. 8(2). e000990–e000990. 18 indexed citations

14.

Larson, Rebecca C., Ana P. Castaño, Amanda A. Bouffard, et al.. (2020). Bispecific CAR T cells for multiple myeloma: natural ligand compared to tandem scFv design. The Journal of Immunology. 204(1_Supplement). 246.3–246.3. 3 indexed citations

15.

Boroughs, Angela C., Rebecca C. Larson, Nemanja D. Marjanovic, et al.. (2020). A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. Molecular Therapy. 28(12). 2577–2592. 62 indexed citations

16.

Schmidts, Andrea, Maria Ormhøj, Bryan D. Choi, et al.. (2019). Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Advances. 3(21). 3248–3260. 85 indexed citations

17.

Choi, Bryan D., Xiaoling Yu, Ana P. Castaño, et al.. (2019). CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nature Biotechnology. 37(9). 1049–1058. 426 indexed citations breakdown →

18.

Boroughs, Angela C., Rebecca C. Larson, Bryan D. Choi, et al.. (2019). Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. JCI Insight. 4(8). 104 indexed citations

19.

Larson, Rebecca C., Isabelle Lavenir, Teresa Larson, et al.. (1996). Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.. The EMBO Journal. 15(5). 1021–1027. 173 indexed citations

20.

Larson, Rebecca C., George G. Ignotz, & W. B. Currie. (1992). Transforming growth factor β and basic fibroblast growth factor synergistically promote early bovine embryo development during the fourth cell cycle. Molecular Reproduction and Development. 33(4). 432–435. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact